Skip to main content

Table 3 Comparison of sugammadex and neostigmine on OR efficiency and clinical outcomes in an OR over 1 month in the reversal of moderate neuromuscular block

From: A discrete event simulation model of clinical and operating room efficiency outcomes of sugammadex versus neostigmine for neuromuscular block reversal in Canada

Outcome Measure

Neostigmine

Sugammadex (2 mg/kg)

% of patients verified to have full neuromuscular recovery (TOF ratio ≥ 0.9) prior to extubation

0%

5%

10%

25%

50%

75%

100%

OR efficiency outcomes

 Number of OR minutes saved per day

0

3

6

15

31

46

62

 % of days all procedures are completed within the regular OR day

40.6%

40.6%

40.8%

42.7%

49.0%

58.0%

65.0%

72.7%

 Number of procedures performed

90.8

90.8

90.9

91.0

91.6

92.5

92.9

93.0

 Procedures cancelled due to lack of OR time

3.5

3.5

3.4

3.3

2.8

1.9

1.4

1.1

 Procedures cancelled for other reasons

10.7

10.7

10.7

10.8

10.7

10.6

10.8

11.0

 Paid hours of staff over-time

57.8

57.8

57.4

54.9

47.9

38.9

31.9

24.3

Clinical outcomes

 Cases of residual blockade avoided

51

48

46

38

25

13

0

 Hypoxemia cases avoideda

12

12

11

9

6

3

0

 Upper airway obstruction cases avoideda

23

21

20

17

11

6

0

 Absolute reduction in risk of residual blockade, per patient

56%

53%

50%

42%

28%

14%

0%

  1. OR Operating room
  2. aIncludes both cases which are and are not clinically diagnosed and managed